Condition: Mild Cognitive Impairment · Alzheimer Disease · Sponsor: University of California, Davis
Development of novel disease-modifying therapies for Alzheimer's disease (AD) remains of paramount importance. This study will be a Phase II randomized clinical trial testing Senicapoc in patients with mild or prodromal AD. This will be a small Proof of Mechanism study to prove biological activity and target engagement in humans with early AD. The investigators will study up to 55 patients over 52 weeks, with primary outcomes being Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) scores and blood and cerebrospinal fluid (CSF) markers of neuroinflammation. This pilot study will provide an estimate of treatment effect size on cognitive trajectory, daily function, and brain atrophy.
This description comes directly from the study's public registry record.
Rita Venua · (916) 734-1708 · rmvenua@ucdavis.edu
Selene Leal Carrillo · (925) 357-6914 · slealcarrillo@ucdavis.edu
Always discuss trial participation with your own doctor first.
| University of California, Davis Alzheimer's Disease Center | Sacramento, California, United States | Recruiting |
| UC Davis Alzheimer's Disease Center East Bay | Walnut Creek, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04804241